ACQUISITIONS AND DIVESTITURES - Narrative (Details) $ / shares in Units, $ in Thousands				3 Months Ended	9 Months Ended
	Aug. 02, 2022 USD ($) $ / shares shares	May 02, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) test	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jun. 23, 2021	May 03, 2021
Business Acquisition [Line Items]
Contingent consideration			$ 359,021	$ 305,925	$ 305,925
Noncash or part noncash divestiture, amount of consideration received, fair value (in dollars per share) | $ / shares	$ 6.70
Intangibles, net			$ 844,411	727,690	727,690
Period of lab testing services	24 months
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Oncotype DX Genomic Prostate Score Test
Business Acquisition [Line Items]
Total consideration	$ 29,631
Noncash or part noncash divestiture, amount of consideration received (in shares) | shares	691,171
Contingent consideration, additional outcomes, value high	$ 70,000
Intangibles, net	$ 42,900
Disposal group, not discontinued operation, gain (loss) on disposal				$ 13,200	$ 13,200
OmicEra
Business Acquisition [Line Items]
Business acquisition, equity interest issued or issuable (in shares) | shares		265,186
Shares issued, price per share (in usd per share) | $ / shares		$ 55.78
Contingent payment obligations		$ 6,000
Contingent consideration		4,600
Developed technology		$ 10,000
Weighted-average remaining useful life of finite-lived intangible asset (in years)		16 years
PreventionGenetics acquisition
Business Acquisition [Line Items]
Number of tests provided | test			5,000
PFS Genomics
Business Acquisition [Line Items]
Asset acquisition, percentage of interest acquired							90.00%
Remaining interest in PFS						10.00%